In addition, the beneficial effects of MSCs in GN appear to be mediated by modification of the Th1/Th2 and/or Th17/Treg balance and inhibition of B-cell activation, as well as stimulation of IL-10, IL-4, foxp3, prostaglandin E2 (PGE2), and TGF-β production (Ma et al., 2013; Suzuki et al., 2013). The gene discussed is IL4; the disease is ganglioneuroma.